Fracture intervention trial research group

Objective: To evaluate the ability of self-reported risk factors to identify postmenopausal women likely to have extant vertebral fractures because approximately two thirds of women with radiographic evidence of vertebral fracture are unaware of the fracture. Patients and methods: Questionnaire and spinal radiographic data were collected from postmenopausal women with a femoral neck bone mineral density T score of Logistic regression was used to identify risk factors for extant vertebral fractures and to derive a final multivariable model.

The final model consisted of 5 self-reported items: history of vertebral fracture, history of nonvertebral fracture, age, height loss, and diagnosis of osteoporosis. The prevalence of women with vertebral fracture varied from 3. Background: Previous studies have shown that alendronate can increase bone mineral density BMD and prevent radiographically defined morphometric vertebral fractures.

The Fracture Intervention Trial aimed to investigate the effect of alendronate on the risk of morphometric as well as clinically evident fractures in postmenopausal women with low bone mass. Methods: Women aged with low femoral-neck BMD were enrolled in two study groups based on presence or absence of an existing vertebral fracture. Results for women with at least one vertebral fracture at baseline are reported here.

The dose of alendronate initially 5 mg daily was increased to 10 mg daily at 24 months, with maintenance of the double blind. Lateral spine radiography was done at baseline and at 24 and 36 months. Non-spine clinical fractures were confirmed by radiographic reports.